Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis

NCT00530075 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Wegener's Granulomatosis

Interventions

DRUG: Gusperimus

Sponsor

Nippon Kayaku Co., Ltd.